Products & Tech | Page 49 of 63

Biodel to Accelerate Development of Ultra-Rapid-Acting Insulins

Biodel Inc. has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed...

Positive Results for Once Monthly Type 2 Diabetes Drug

Positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes were announced by Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. Exenatide once monthly is a new...

Type 2 Diabetes Drug, ONGLYZA, Approved for Treatment of Renal Impairment by EU

The European Commission approved a label update for ONGLYZA® (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment following results of a new study submitted by AstraZeneca and Bristol-Myers Squibb Company. The approved dosage for the patient group is a new once-daily 2.5 mg dose...

Abbott Announces Positive Results in Phase 2 Study of Atrasentan in Treatment of Diabetic Kidney Disease

Abbott has announced positive results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease. The results suggest that atrasentan, used in conjunction with renin-angiotensin system (RAS) inhibitors, may reduce albuminuria (presence of protein in urine) for patients with type 2 diabetes....

Amylin’s Type 2 Diabetes Drug, BYDUREON, Fails to Meet Primary End Point in New Study

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the top-line results from the DURATION-6 study comparing once weekly BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, to Novo Nordisk's daily Victoza (liraglutide (rDNA origin) injection). Both drugs are members of the class of type 2 diabetes medications known as glucagon-like peptide-1 (GLP-1) receptor agonists...

Roche Recalls ACCU-CHEK FlexLink Plus Insulin Delivery Systems

Roche Insulin Delivery Systems is recalling ACCU-CHEK FlexLink Plus infusion sets because of the potential for under delivery of insulin. The problem is due to a kinked/bent cannula when inserting the infusion set. If this remains unnoticed it can result in under delivery of insulin leading to elevation of blood glucose levels...

Use the First Drop of Blood

A recent study published in Diabetes Care investigated whether capillary glucose concentrations, as measured in the first and second drops of blood, differed more than 10 percent when compared with a control glucose concentration in different situations.

Bariatric Surgery May be Best Treatment for Type 2 Diabetes

A new clinical trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is among the first to test surgery specifically for type 2 diabetes. The aim of the study is to understand whether surgery can control diabetes, as well or even better than the best medical treatment available today. This is the first study of its kind open to patients who are overweight or mildly obese...

Positive Results for New Sanofi-aventis Type 2 Diabetes Drug

Sanofi-aventis announced that the GetGoal-X Phase 3 study of lixisenatide, a once-daily GLP-1 receptor agonist, has achieved primary efficacy endpoint. Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus.

Novo Nordisk’s New Insulin Pen for Children Wins GOOD DESIGN Award

The Chicago Athenaeum Museum of Architecture and Design in cooperation with The European Centre for Architecture, Art, Design and Urban Studies have chosen to award Novo Nordisk a 2010 GOOD DESIGN™ Awardfor the NovoPen Echo, a new insulin pen designed specifically with the needs of children in mind...